Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 197. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 32. We strongly support the language in the Bill which allows a pharmacist to substitute an FDA approved “interchangeable biological product”.
The recommendations included in this letter are based upon consensus recommendations of an Academy of Managed Care Pharmacy (AMCP) Partnership Forum, Advancing ValueBased Contracting (VBC), held in June 2017.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Assembly Bill 679 and Senate Bill 575. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The undersigned organizations write to voice our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212) and encourage Congress to pass this important, bipartisan legislation as soon as possible.
The Academy of Managed Care Pharmacy (AMCP) thanks the FDA for the opportunity to provide comments before the Opioid Policy Steering Committee. AMCP commends the FDA for establishing the OPSC and for seeking public input to help identify key areas of focus that the FDA can address.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to submit a letter of support for H.R. 2026 – The Pharmaceutical Information Exchange (PIE) Act of 2017 which will improve patient access to emerging medication therapies and devices by codifying a safe harbor for certain health care economic and scientific information communications between biopharmaceutical and medical device manufacturers and population health decision makers.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4472 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services for the opportunity to provide comments in response to the proposed rule “Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program [CMS-4182-P]” published in the Federal Register on November 28, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for suggestions, recommendations and comments relevant to the FDA’s newly established Opioid Policy Steering Committee (OPSC) as published in the Federal Register on September 29, 2017.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide information on the application of value-based contracts (VBCs) for insulin pricing initiatives. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Federal Trade Commission (FTC) for the opportunity to provide comments in response to the request for comments titled “Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics” released on October 18, 2017.
